2 ANNEX II Case definitions for the communicable diseases and related special health issues subject to epidemiological surveillance, as referred to in Article 2, Regulation (EU) 2026/2097

In forcesince 18 Sep 2026

Clinical criteria include common and relevant signs and symptoms of the disease which either individually or in combination constitute a clear or indicative clinical picture of the disease. They give the general outline of the disease and do not necessarily indicate all the features needed for individual clinical diagnosis.

Laboratory criteria are a list of laboratory methods that are used to confirm a case. Usually only one of the listed methods is sufficient to confirm the case. If a combination of methods is needed to meet the laboratory confirmation, this is specified. The type of specimen to be collected for laboratory testing is only specified when only certain specimen types are considered relevant for the confirmation of a diagnosis. Laboratory criteria for a probable case are included for some agreed exceptional cases. Those laboratory criteria consist of a list of laboratory methods which can be used to support the diagnosis of a case but which are not confirmatory.

Epidemiological criteria shall be deemed to have been met when an epidemiological link can be established. Epidemiological link, during the incubation period, means one of the following six:

Human-to-human transmission: the fact that a person has had contact with a laboratory-confirmed human case (or, for some diseases, a person suspected to have been exposed due to their travel history) in such a way as to have had the opportunity to acquire the infection;

Animal-to-human transmission: the fact that a person has had contact with an animal with a suspected infection or colonisation in such a way as to have had the opportunity to acquire the infection;

Exposure to a common source: the fact that a person has been exposed to the same common source or vehicle of infection, as a confirmed human case;

Exposure to contaminated food/drinking water: the fact that a person has consumed food or drinking water with a laboratory-confirmed contamination or has consumed potentially contaminated products from an animal with a suspected infection or colonisation;

Environmental exposure: the fact that a person has bathed in water or has had contact with a contaminated environmental source that has been confirmed by a laboratory;

Laboratory exposure: the fact that a person has worked in a laboratory where there is a potential for exposure.

A person shall be considered epidemiologically linked to a confirmed case if at least one case in the chain of transmission is confirmed by a laboratory. In case of an outbreak of faeco-oral or airborne transmitted infections, a case may be considered epidemiologically linked without establishing the chain of transmission.

Transmission may occur by one or more of the following routes:

Airborne: by projection of aerosol from an infected person onto the mucous membranes while coughing, spitting, singing or talking, or when microbial aerosols dispersed into the atmosphere are inhaled by others;

Contact: direct contact with an infected person (faecal-oral, respiratory droplets, skin or sexual exposure) or animal (for example, biting, touching) or indirect contact to infected materials or objects (fomites, body fluids, blood);

Vertical: from mother to child, often in utero, or as a result of the incidental exchange of body fluids usually during the perinatal period;

Vector transmission: transmission by infected mosquitoes, ticks, mites, flies and other insects which transmit disease to humans through their bites;

Food or water: consumption of potentially contaminated food or drinking water.

Cases shall be classified as ‘possible’, ‘probable’ and ‘confirmed’. The incubation periods for diseases are given in the additional information to facilitate the assessment of the epidemiological link.

A possible case means a case classified as possible for reporting purposes. It is usually a case meeting the clinical criteria as described in the case definition without epidemiological or laboratory evidence of the disease in question. The definition of a case as possible has high sensitivity and low specificity. It allows for detection of most cases but some false positives cases will be included into this category.

A probable case means a case classified as probable for reporting purposes. It is usually a case with clinical criteria and an epidemiological link as described in the case definition. Laboratory tests for probable cases are specified only for some diseases.

A confirmed case means a case classified as confirmed for reporting purposes. Confirmed cases are confirmed by a laboratory and may or may not fulfil the clinical criteria as described in the case definition. The definition of a case as confirmed is highly specific and less sensitive; therefore, most of the collected cases will be true cases although some will be missed.

The clinical criteria of some diseases do not allude to the fact that many acute cases are asymptomatic (for example, hepatitis A, B and C, campylobacteriosis, salmonellosis) although these cases may still be important from a public health perspective on national level.

Any person meeting the clinical criteria

AND

At least one of the following three:

despite an adequate specimen collected and tested by a proficient laboratory, the case does not meet the case definition laboratory criteria for the disease in question;

the case is epidemiologically linked to a laboratory-confirmed case or outbreak of another communicable disease than the disease in question;

another disease aetiology is confirmed in the case, even if the case is epidemiologically linked to a laboratory-confirmed case or another epidemiologically linked case of the disease in question.

Note: For some of the conditions under surveillance, the structure of the case definitions does not follow the typical structure of the case definition such as in the cases of variant Creutzfeldt-Jakob disease (vCJD), healthcare-associated infections and antimicrobial resistance.

1.

AFP: acute flaccid paralysis

2.

AIDS: acquired immune deficiency syndrome

3.

AMR: antimicrobial resistance

4.

Anti-HBc: hepatitis B core antibody

5.

anti-HCV: hepatitis C virus specific antibody

6.

ARI: acute respiratory infection

7.

BAL: broncho-alveolar lavage

8.

BCG: Bacille de Calmette et Guérin

9.

BJ: bone and joint infection

10.

BJ-BONE: osteomyelitis

11.

BJ-DISC: disc space infection

12.

BJ-JNT: joint or bursa infection

13.

BoNT: botulinum neurotoxin

14.

BSI: bloodstream infection

15.

C-CVC: catheter-related — central venous catheter

16.

CDAD: Clostridioides difficile associated diarrhoea

17.

CFU: colony-forming unit

18.

CMV: cytomegalovirus

19.

CNS: central nervous system

20.

CNS-IC: central nervous system infection — intracranial infection

21.

CNS-MEN: central nervous system infection — meningitis or ventriculitis

22.

CNS-SA: central nervous system infection — spinal abscess without meningitis

23.

C-PVC: catheter-related — peripheral venous catheter

24.

CRI: catheter-related infection

25.

CRS: Congenital rubella syndrome

26.

CRT: capillary refilling time

27.

CSF: Cerebrospinal fluid

28.

CT scan: computed tomography scan

29.

CVS: cardiovascular system infection

30.

CVS-CARD: cardiovascular system infection — myocarditis or pericarditis

31.

CVS-ENDO: cardiovascular system infection — endocarditis

32.

CVS-MED: cardiovascular system infection — mediastinitis

33.

CVS-VASC: cardiovascular system infection — arterial or venous infection

34.

DFA: direct fluorescent antibody

35.

DFA-TP: direct fluorescent antibody test for Treponema pallidum

36.

DNA: deoxyribonucleic acid

37.

DPA: distal protected aspirate

38.

EARS-Net: European Antimicrobial Resistance Surveillance Network

39.

ECDC: European Centre for Disease Prevention and Control

40.

ECOFFs: epidemiological cut-off values

41.

EEG: electroencephalography

42.

EENT: eye, ear, nose, throat, or mouth infection

43.

EENT-CONJ: eye, ear, nose, throat, or mouth infection — conjunctivitis

44.

EENT-EAR: eye, ear, nose, throat, or mouth infection — ear and mastoid

45.

EENT-EYE: eye, ear, nose, throat, or mouth infection — eye, other than conjunctivitis

46.

EENT-ORAL: eye, ear, nose, throat, or mouth infection — oral cavity (mouth, tongue, or gums)

47.

EENT-SINU: eye, ear, nose, throat, or mouth infection — sinusitis

48.

EENT-UR: eye, ear, nose, throat, or mouth infection — upper respiratory tract, pharyngitis, laryngitis, epiglottitis

49.

EFNS: European Federation of Neurological Societies

50.

EIA: enzyme immunoassay

51.

ELISA: enzyme-linked immunosorbent assay

52.

EM: electron microscopy

53.

ERLI-Net: European Reference Laboratory Network for Human Influenza

54.

EUCAST: European Committee on Antimicrobial Susceptibility Testing

55.

FAMA: fluorescent antibody to membrane antigen

56.

FTA-abs: fluorescent treponemal antibody absorption

57.

FUO: fever of unknown origin

58.

GI: gastrointestinal system infection

59.

GI-CDI: gastrointestinal system infection — Clostridioides difficile infection

60.

GI-GE: gastrointestinal system infection — gastroenteritis (excl. CDI)

61.

GI-GIT: gastrointestinal system infection — gastrointestinal tract (esophagus, stomach, small and large bowel, and rectum) excluding gastroenteritis and appendicitis

62.

GI-HEP: gastrointestinal system infection — hepatitis

63.

GI-IAB: gastrointestinal system infection — intraabdominal, not specified elsewhere including gallbladder, bile ducts, liver (excluding viral hepatitis), spleen, pancreas, peritoneum, subphrenic or subdiaphragmatic space, or other intraabdominal tissue or area not specified elsewhere

64.

HAI: healthcare-associated infections

65.

HbeAg: hepatitis B e antigen

66.

HbsAg: hepatitis B surface antigen

67.

HBV-DNA: hepatitis B deoxyribonucleic acid

68.

HCV-core: hepatitis C virus core antigen

69.

HCV-RNA: hepatitis C virus ribonucleic acid

70.

HIV: human immunodeficiency virus

71.

HUS: haemolytic-uraemic syndrome

72.

IAP: intubation-associated pneumonia

73.

IF: immunofluorescence

74.

IFA: indirect fluorescent antibody

75.

IgG: immunoglobulin G

76.

IgM: immunoglobulin M

77.

ILI: influenza-like illness

78.

LGV: lymphogranuloma (venereum)

79.

LPS: lipopolysaccharides

80.

LRI: lower respiratory tract infection, other than pneumonia

81.

LRI-BRON: lower respiratory tract infection — bronchitis, tracheobronchitis, bronchiolitis, tracheitis, without evidence of pneumonia

82.

TBE: Tick-borne encephalitis

83.

vCJD: variant Creutzfeldt-Jakob disease

Any person with at least one of the following clinical forms:

At least one the following two:

Papular or vesicular lesion;

Depressed black eschar with surrounding oedema.

Fever or feverishness;

AND at least one of the following two:

Severe abdominal pain;

Diarrhoea.

Fever or feverishness;

AND at least one of the following two:

Acute respiratory distress;

Radiological evidence of mediastinal widening.

Fever;

AND at least one of the following three:

Convulsions;

Loss of consciousness;

Meningeal signs.

At least one of the following two:

Isolation of Bacillus anthracis from a clinical specimen;

Detection of Bacillus anthracis nucleic acid in a clinical specimen.

Positive nasal swab without clinical symptoms shall not contribute to a confirmed diagnosis of a case.

At least one of the following three epidemiological links:

Animal-to -human transmission;

Exposure to a common source;

Exposure to contaminated food/drinking water.

A. Possible case NA

B. Probable case

Any person meeting the clinical criteria with an epidemiological link.

C. Confirmed case

Any person meeting the clinical and the laboratory criteria.

Note: If the national surveillance system is not capturing clinical symptoms, all laboratory-confirmed individuals shall be reported as confirmed cases.

Clinical manifestations compatible with arenavirus infection (for example, fever, gastrointestinal symptoms, haemorrhagic manifestations, neurological manifestations)

Detection of anti-arenavirus IgM antibodies in a single serum sample.

At least one of the following four:

Isolation and identification of arenavirus from a clinical specimen;

Detection of arenavirus nucleic acid from a clinical specimen;

Detection of arenavirus antigen from a clinical specimen;

Detection of acute infection through serological methods: arenavirus-specific seroconversion OR four-fold antibody titre increase in paired serum samples OR low-avidity IgG antibodies in a serum sample.

Identification of the virus species should be performed, if possible.

At least one of the following three:

Residing in, or having visited within the four-week period prior to the onset of symptoms, an area where arenavirus transmission has previously occurred;

Having been exposed to arenavirus infectious material during an occupation (for example laboratory work);

Having had contact with possibly infected rodents, their excreta or fomites within the four-week period prior to the onset of symptoms in an area where arenavirus transmission has previously occurred.

A. Possible case NA

B. Probable case

Any person meeting the laboratory criteria for a probable case AND at least one of the following two:

clinical criteria;

epidemiological criteria.

C. Confirmed case

Any person meeting the laboratory criteria for a confirmed case.

Any person with at least one of the following clinical forms:

At least one of the following two:

Bilateral cranial nerve impairment (for example, diplopia, blurred vision, dysphagia, bulbar weakness);

Peripheral symmetric paralysis.

Any infant with at least one of the following six:

Constipation;

Lethargy;

Difficulty in sucking or feeding;

Ptosis;

Dysphagia;

General muscle weakness.

The type of botulism usually encountered in infants (< 12 months of age) can also affect children over 12 months of age and rarely adults with altered gastrointestinal anatomy and microflora.

At least one of the following three:

Isolation of BoNT-producing clostridia (for example, Clostridium botulinum, C. baratii, C. butyricum) for infant botulism (stool) or wound botulism (wound);

Detection of botulinum neurotoxins in a clinical specimen;

Detection of genes encoding for botulinum neurotoxins in a clinical specimen.

At least one of the following three epidemiological links:

Exposure to a common source (for example, food, sharing of needles or other devices);

Exposure to contaminated food/drinking water;

Exposure to botulinum neurotoxin for cosmetic or medical reasons.

A. Possible case NA

B. Probable case

Any person meeting the clinical criteria with an epidemiological link.

C. Confirmed case

Any person meeting the clinical and the laboratory criteria.

Any person with fever

AND at least one of the following seven:

Sweating (profuse, malodorous, specially nocturnal);

Chills;

Arthralgia;

Weakness;

Depression;

Headache;

Anorexia.

At least one of the following three:

Isolation of human pathogenic Brucella spp. from a clinical specimen;

Human pathogenic Brucella specific antibody response (standard agglutination test, complement fixation, ELISA);

Detection of human pathogenic Brucella spp. nucleic acid in a clinical specimen.

At least one of the following five epidemiological links:

Exposure to contaminated food/drinking water;

Exposure to products from a contaminated animal (milk or milk products);

Animal-to-human transmission (contaminated secretions or organs, for example, vaginal discharge, placenta);

Exposure to a common source;

Laboratory exposure.

A. Possible case NA

B. Probable case

Any person meeting the clinical criteria with an epidemiological link.

C. Confirmed case

Any person meeting the clinical and the laboratory criteria.

Note: If the national surveillance system is not capturing clinical symptoms, all laboratory-confirmed individuals shall be reported as confirmed cases.

Any person with at least one of the following three:

Diarrhoea;

Abdominal pain;

Fever.

At least one of the following two:

Isolation of human pathogenic Campylobacter spp. from a clinical specimen;

Detection of Campylobacter spp. nucleic acid in a clinical specimen.

Note: Antimicrobial susceptibility testing of Campylobacter spp. should be performed on a representative subset of isolates.

At least one of the following five epidemiological links:

Animal-to-human transmission;

Human-to-human transmission;

Exposure to a common source;

Exposure to contaminated food/drinking water;

Environmental exposure.

A. Possible case NA

B. Probable case

Any person meeting the clinical criteria with an epidemiological link.

C. Confirmed case

Any person meeting the clinical and the laboratory criteria.

Note: If the national surveillance system is not capturing clinical symptoms, all laboratory-confirmed individuals shall be reported as confirmed cases.

The results of antimicrobial susceptibility tests shall be reported according to the methods and criteria agreed between the ECDC and the Member States as specified in the EU protocol for harmonised monitoring of antimicrobial resistance in human Salmonella and Campylobacter isolates (https://ecdc.europa.eu/en/publications-data/eu-protocol-harmonised-monitoring-antimicrobial-resistance-human-salmonella-and-0).

Clinical manifestations compatible with chikungunya virus disease (for example, fever, rash, joint pain).

Detection of anti-chikungunya virus IgM antibodies in a single serum sample.

At least one of the following four:

Isolation and identification of chikungunya virus from a clinical specimen;

Detection of chikungunya viral antigen from a clinical specimen;

Detection of chikungunya viral nucleic acid from a clinical specimen;

Detection of acute infection through serological methods (for example, IgM antibodies in a single serum sample, seroconversion or four-fold antibody titre increase in paired serum samples, low-avidity IgG antibodies in a serum sample), AND confirmation of the specificity of antibodies by simultaneous neutralisation assays with serologically cross-reacting viruses, or with other equivalently discriminatory method.

At least one of the following two:

Residing in, or having visited within the two-week period prior to the onset of symptoms, an area where chikungunya virus transmission has previously occurred;

Having received substances of human origin from a donor who has resided or visited (within the four-week period before donation) an area where chikungunya virus disease has previously been detected.

A. Possible case NA

B. Probable case

Any person meeting the laboratory criteria for a probable case AND at least one of the following two:

clinical criteria;

epidemiological criteria.

C. Confirmed case

Any person meeting the laboratory criteria for a confirmed case.

Note: Serological results should be interpreted according to previous exposure to other alphaviral infections. Confirmed cases in such situations should be validated by serum neutralisation assay or other equivalent assays.

Any person with at least one of the following clinical forms:

At least one of the following ten:

Urethritis;

Epididymitis;

Pelvic inflammatory disease;

Acute salpingitis;

Acute endometritis;

Cervicitis;

Proctitis;

Purulent conjunctivitis;

Reactive arthritis;

Perihepatitis.

In newborn children at least one of the following two:

Conjunctivitis;

Pneumonia.

At least one of the following five:

Urethritis;

Genital ulcer;

Inguinal lymphadenopathy;

Cervicitis;

Proctitis/Proctocolitis.

At least one of the following three:

Detection of Chlamydia trachomatis nucleic acid in a clinical specimen;

Isolation of Chlamydia trachomatis from a clinical specimen;

Detection of Chlamydia trachomatis by direct fluorescent antibody (DFA) test in a clinical specimen.

At least one of the following two:

Detection of Chlamydia trachomatis nucleic acid in a clinical specimen;

Isolation of Chlamydia trachomatis from a clinical specimen;

AND

Identification of a Chlamydia trachomatis strain.

An epidemiological link by human-to-human transmission (sexual contact or vertical transmission).

A. Possible case NA

B. Probable case

Any person meeting the clinical criteria with an epidemiological link.

C. Confirmed case

Any person meeting the laboratory criteria.

Any person with at least one of the following two:

Diarrhoea;

Vomiting.

At least one of the following two:

Isolation of Vibrio cholerae from a clinical specimen;

Detection of Vibrio cholerae nucleic acid in a clinical specimen;

AND

At least one of the following two:

Demonstration of O1 or O139 antigen in the isolate;

Detection of the O1 or O139 gene(s) in the isolate or clinical specimen;

AND

Demonstration of cholera-enterotoxin production or detection of the cholera-enterotoxin gene in the isolate or clinical specimen.

At least one of the following four epidemiological links:

Exposure to a common source;

Human-to-human transmission;

Exposure to contaminated food/drinking water;

Environmental exposure.

A. Possible case NA

B. Probable case

Any person meeting the clinical criteria with an epidemiological link.

C. Confirmed case

Any person meeting the clinical and the laboratory criteria.

Note: If the national surveillance system is not capturing clinical symptoms, all laboratory-confirmed individuals shall be reported as confirmed cases.

Any person with a progressive neuropsychiatric disorder with a duration of illness of at least 6 months;

Routine investigations do not suggest an alternative diagnosis;

No history of exposure to human pituitary hormones or human dura mater graft;

No evidence of a genetic form of transmissible spongiform encephalopathy.

Any person with at least four of the following five:

Early psychiatric symptoms [Depression, anxiety, apathy, withdrawal, delusions.];

Persistent painful sensory symptoms [This includes both frank pain and/or dysaesthesia.];

Ataxia;

Myoclonus or chorea or dystonia;

Dementia.

Neuropathological confirmation: spongiform change and extensive prion protein deposition with florid plaques throughout the cerebrum and cerebellum.

EEG does not show the typical appearance of sporadic CJD [The typical appearance of the EEG in sporadic CJD consists of generalised periodic complexes at approximately one per second. These may occasionally be seen in the late stages of vCJD.] in the early stages of the illness;

Bilateral pulvinar high signal on MRI brain scan;

A positive tonsil biopsy [Tonsil biopsy is not recommended routinely nor in cases with EEG appearances typical of sporadic CJD but may be useful in suspect cases in which the clinical features are compatible with vCJD and MRI does not show pulvinar high signal. Tonsil biopsy testing should be based on immunohistochemistry or Western Blot.].

An epidemiological link by human-to-human transmission (for example, blood transfusion).

A. Possible case

Any person fulfilling the preconditions AND

meeting the clinical criteria AND

a negative EEG for sporadic CJD [The typical appearance of the EEG in sporadic CJD consists of generalised periodic complexes at approximately one per second. These may occasionally be seen in the late stages of vCJD.].

B. Probable case

Any person fulfilling the preconditions AND

meeting the clinical criteria AND

a negative EEG for sporadic CJD AND

This article is long: the rest is at the official publication.